Tg Therapeutics (TGTX) Other Non-Current Liabilities (2010 - 2026)
Tg Therapeutics (TGTX) posted quarterly Other Non-Current Liabilities of $777000.0 for Q1 2026, down 64.08% year-over-year from $2.2 million in Q1 2025, and down 63.02% quarter-over-quarter from $2.1 million in Q4 2025.
Tg Therapeutics (TGTX) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Tg Therapeutics' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $777000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 64.08% year-over-year to $777000.0; the TTM figure through Mar 2026 stood at $777000.0 (down 64.08% YoY), while the FY2025 annual figure was $2.1 million, down 44.56% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $777000.0, down from $2.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $3.8 million in Q4 2024, with the low at $243000.0 in Q4 2022.
- The 5-year median for Other Non-Current Liabilities is $2.2 million (2025), against an average of $2.1 million.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities surged 961.62% in 2024, then sank 64.08% in 2026.
- Tg Therapeutics' Other Non-Current Liabilities stood at $243000.0 in 2022, then soared by 46.91% to $357000.0 in 2023, then soared by 961.62% to $3.8 million in 2024, then sank by 44.56% to $2.1 million in 2025, then plunged by 63.02% to $777000.0 in 2026.
- Business Quant data shows TGTX's Other Non-Current Liabilities at $777000.0 in Q1 2026, $2.1 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Mn |
| Mar 31, 2026 | 777,000.00 |
| Dec 31, 2025 | 2.10 Mn |
| Sep 30, 2025 | 1.96 Mn |
| Jun 30, 2025 | 2.21 Mn |
| Mar 31, 2025 | 2.16 Mn |
| Dec 31, 2024 | 3.79 Mn |
| Sep 30, 2024 | 3.08 Mn |
| Jun 30, 2024 | 3.08 Mn |
| Mar 31, 2024 | 2.79 Mn |
| Dec 31, 2023 | 357,000.00 |
| Dec 31, 2022 | 243,000.00 |
| Dec 31, 2021 | 360,000.00 |
| Sep 30, 2021 | 623,000.00 |
| Jun 30, 2021 | 717,000.00 |
| Mar 31, 2021 | 880,000.00 |
| Dec 31, 2020 | 938,000.00 |
| Sep 30, 2020 | 477,000.00 |
| Jun 30, 2020 | 343,000.00 |
| Mar 31, 2020 | 171,000.00 |